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ABSTRACT 
It is a myth that electroconvulsive therapy (ECT) produces greater side effects and worsens the 
neurological condition when used in neurologically ill patients. With the advancement and sophistication 
in ECT practice standards and modification procedures, it can be safely administered either to treat 
selected neurological conditions or the co-morbid psychiatric illnesses without additional risks. However 
EC T should be administered only after thorough evaluation of risks and benefits in such individuals. 
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Electroconvulsive therapy (ECT) is a 
technique to induce convulsions for therapeutic 
purposes using pulsed direct current. Use of ECT 
in the treatment of major psychiatric illnesses has 
been established (Abrams,1997). ECT is also 
useful in the treatment of co-morbid psychiatric 
illnesses associated with various neurological 
conditions (Dubovsky,1986). In addition ECT 
seems to hold promise for the treatment of certain 
neurological disorders (Gangadharetal.,2001). 
Patients with neurological disorder may 
have either a primary or secondary psychiatric 
illness (Lishman, 1998). Approach towards 
underlying aetiology is important in all such cases. 
However, many such patients need additional 
psychiatric intervention. It may be counselling, 
psychotropic drug or ECT In general, ECT may 
produce a transient organic mental syndrome in 
nearly 50 percent of cases (Summers et al.,1979). 
If such were the case one would find it strange to 
use this treatment in patients with conditions 
affecting the structure or function of the brain. In 
practice however, ECT has been found to produce 
fewer adverse effects than might intuitively be 
expected (Turek and Hanlon,1977). Recently 
conducted neuroimaging studies found no 
changes in the brain structure or brain water 
content after ECT (Girish ,1999). Thus ,use of ECT 
in neurological conditions may be safe. This article 
briefly reviews the use of ECT in the treatment of 
neurological disorders and associated co-morbid 
psychiatric illnesses. 
Delirium and epilepsy: For management, the 
underlying cause for delirium must be evaluated, 
while antiepileptics form the mainstay in the 
treatment of epilepsy. In both these conditions 
prolongation of the illness and / or inadequate 
control increases risk of mortality. Though rarely 
used, ECT is found to be helpful in such 
conditions. 
Delirium: At least 10% of individuals receiving 
ECT have acute confusional state/delirium 
(Abrams,1977). The factors that increase the risk 
of ECT-induced delirium are male sex, higher age, 
first ECT session, bilateral electrode placement 
and concurrent use of psychotropic drugs like 
lithium. Besides this, ECT has been proven to be 
of use in patients with delirium not adequately 
responding to medications. Benzodiazepines or 
antipsychotic drugs are used to manage confusion, 
agitation, disruptive behaviour and hallucinations 
in delirious patients. However, their side effects, 
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in particular, the extrapyramidal side effects (with 
neuroleptics)must be monitored. When delirium 
is marked and persistent, ECT can be used as 
an alternative. Patients with delirium due to head 
injury, meningitis, encephalitis, pneumonia, 
delirium tremens, porphyria, uraemia, Wernicke's 
encephalopathy and who have inadequately 
responded to drugs (e.g.barbiturate, phencyclidine 
or bromides) were treated sucessfully with ECT 
(Dubovsky, 1986). Though ECT- induced 
complications (prolonged and severe confusion, 
amnesic effects) are higher in patients with pre-
existing neurological disorder (Krystal and Coffey, 
1997), none of these patients had such 
complications. Delirium can also follow cluster 
attacks of epilepsy; ECT was found useful in such 
situations (Dubovsky, 1986). However, the 
approach should be to treat aggressively the 
underlying aetiology for delirium. 
Epilepsy: During the ECT course, seizure 
threshold increases progressively. The threshold 
when reassessed in sixth ECT session is found 
to be one-and half to two times higher than 
threshold at first ECT session (Abrams, 1997). 
This suggests anticonvulsant property of ECT. In 
patients with intractable epilepsy (who are poor 
responders to pharmacological agents) ECT has 
been used with success (Krystal and Coffey, 
1997; Sackeim et al.,1983). There is difference in 
opinion among physicians in altering the 
antiepileptic regime when these patients are 
prescribed ECT. Abrupt reduction or withdrawal 
of anticonvulsants may precipitate seizures/ 
status ( Hauser, 1983). Hence they need to be 
continued during the ECT course. Some advocate 
reduction in the dosage of anticonvulsant 
medication prior to ECT because of its effects on 
seizure threshold and seizure induction. It is better 
to reduce the drugs only when induction of 
seizures is difficult or patient has repeated 
subshocks (American Psychiatric Association, 
2001) The ECT stimulus dose required for seizure 
induction may be higher in patients who are on 
antiepileptic drugs (Roberts and Attah, 1988). The 
morning dose is usually withheld before ECT. 
Blood levels may be monitored and maintaining 
anticonvulsants at the lower end of therapeutic 
range may be at time useful; thereby minimizing 
the interference with ECT seizure induction Serial 
monitoring of blood levels should be considered 
during the ECT course, particularly if levels have 
not been stable in the recent past. 
Epilepsy is associated with high prevalence 
(>30%) of psychiatric co-morbidity (Levin et 
al.,1988), although it is difficult to form an accurate 
estimate. The type of epilepsy and range of 
psychiatric illnesses seen during the lifetime 
course of epileptic individuals compound it. Ictal 
or post-ictal confusional state or psychosis, 
epileptic personality chnage, impulsivity and 
aggressiveness are common. Nearly one-fourth 
may develop depression (Robertson and 
Trimble,1983). Control of seizure is the mainstay 
of treatment in all these cases. ECT is effective in 
epileptic psychosis poorly responding to 
psychotropic drugs. Marked abnormalities of mood 
or florid delusions or hallucinations have better 
response to ECT (Lishman, 1998). ECT can be 
prescribed even in the presence of confusion and 
clouding of consciousness. However, the epileptic 
basis of the disease should be well established 
and other intracranial causes have to be excluded. 
There may be increased risk of prolonged seizures 
during ECT (Devinsky and Duchowny, 1983). 
Stroke and brain tumours: ECT may also be used 
when psychiatric illnesses arise secondary to 
neurological conditions or when they coexist with 
neurological conditions. Stroke and brain tumours 
are some such conditions wherein ECT has been 
found useful to treat the psychiatric illness. 
Stroke: Depression is seen in around 30% of 
patients in the first few weeks following stroke. 
Two-thirds of these have major depression (Burvill 
etal.,1995). This is also the commonest comorbid 
psychiatric illness in patients with stroke. In those 
with severe depression ECT has been found 
useful. ECT produces steep rise in heart rate and 
blood pressure It is presumed that prescribing 
ECT in patients who had a cerebrovascular 
accident or stroke posses additional risk. But 
this has not been seen in practice (Miller and 
Isenberg, 1998). This may be because the rise in 
haemodynamic status due to ECT is transient. 
Although rare, death recorded in the past may be 
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due to co-morbid cardiovascular complications in 
stroke patients (Heshe and Roeder,1976). 
There is hardly an increased risk of cognitive 
impairment with ECT in stroke patients; some 
even reported improvement in their cognitive status 
(Murray et al., 1986). There is however increased 
risk of ECT- induced delirium in patients who had 
stroke (Martin et al., 1992) or MRI hyperintensities 
in basal ganglia (Figiel et al.,1991). To minimize 
any additional risk of ECT- induced complications, 
it is best prescribed at least a month after stroke 
(Murray et al., 1986). ECT in individuals with recent 
stroke or cerebral aneurysm must be avoided. 
The acute ECT-related hypertensive surge should 
be pharmacologically blunted when ECT is given 
for patients at risk for a bleed (Krystal and 
Coffey, 1997). Maintenance of blood pressure within 
fairly narrow range (using p blockers, nitroprusside) 
is required (Allman and Hawton, 1987), in order 
to avoid the potential risk of cerebral bleeding 
with severe hypertension or cerebral ischemia 
with hypotension. Aggressive antihypertensive 
medication may increase the risk of hypotensive 
morbidity. ECT has also been used successfully 
to treat depression in patients with intracerebral 
arterial (Husum et al.,1983; Drop et al.,1988) or 
venous malformations (Greenberg etal.,1986). In 
patients who are on anticoagulant therapy (either 
heparin or warfarin), ECT can be used safely 
without any untoward complications (Abrams, 
1997). However, close monitoring of coagulation 
parameters is mandatory. 
Intracranial space occupying lesions: The 
incidence of psychiatric illness in patients with 
brain tumour can vary between 10% and 100% 
(Lishman, 1998). Large and rapid growing tumours 
produce raised intracranial pressure (ICP). Raised 
ICP is a contraindication for ECT. ECT increases 
the ICP transiently. Though reported, serial 
monitoring of spinal fluid pressure and dynamics 
with ECT did not show any rise( Dressier and 
Folk,1975).Steroids are used to reduce brain 
oedema before prescribing ECT to treat co-morbid 
psychiatric illness in patients with brain tumour 
(Zwil et al.,1990). Small and slow growing 
neoplasms hardly raise ICP (such as 
meningiomas). ECT can be safely administered 
in such cases. On the other hand ECT in 
presence of large and malignant tumours may 
further increase ICP and potentiate adverse effects 
(Fried and Mann, 1998; Zwil et al., 1990). These 
include noncardiogenic pulmonary oedema, 
cerebral oedema, brain haemorrhage, brain 
herniation, neurological deterioration and rarely 
death (Krystal and Coffey, 1997). However such 
events are rare in practice (Maltbie et al.,1980). A 
neurological catastrophe in an apparently healthy 
patient receiving ECT may be the first sign of an 
unsuspected brain tumour. ECT was used 
successfully in the treatment of organic 
depression in patients with other space-occupying 
lesion such as chronic subdural haematoma 
(Malek-Ahmadi et al.,1990) and intracranial 
arachnoid cysts (Escalona et al.,1991) without 
any additional risk. In patients with raised ICP 
one must evaluate the risk benefit ratio in each 
individual case. 
Craniotomy patients with psychiatric illness 
may at times be referred for ECT. Stimulus 
electrodes are placed farthest from the cranial 
defect without any additional special precautions. 
Patients with co-morbid depression in meningioma 
(Hsiao and Evans, 1984), pituitary adenoma (Ries 
and Bokan, 1979), third ventricle colloid cyst 
(Roccaforte and Burke, 1989) or bullet shot injuries 
(Ruedrich et al., 1983) who underwent craniotomy 
improved with ECT. 
Normal pressure hydrocephalus (NPH) may 
present with psychiatric symptoms like 
depression, psychosis or dementia (Lishman, 
1998). These symptoms may quite often predate 
the appearance of classical symptoms of NPH 
(Pujal et al., 1989). Psychiatric illness remits with 
surgical correction of NPH. However, some needed 
ECT for treating depression (Cardno and 
Simpson, 1991) with improvement in neurological 
condition (Mansheim,1983). Other had marked 
post - ECT confusion and memory loss (Price and 
Tucker, 1977). 
Disorders of basal ganglia: Basal ganglia is 
implicated in various psychiatric conditions 
associated with movement disorders. Some of the 
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neurological conditions too arise due to basal 
ganglia pathology. Use of ECT has helped to treat 
both neurological conditions and/or associated 
psychiatric illness. 
Parkinson's Disease: The commonest 
degenerative disorder of basal ganglia is 
Parkinson's disease (PD). It is more prevalent after 
forty years of age and males outnumber females. 
They typically present with rigidity, tremors, 
bradykinesia and postural instability. 
Hypodopaminergic state is a well-established 
aetiology in these patients (Adams et al.,1977). 
Among all the neurological conditions, use 
of ECT in the treatment of neurological symptoms 
of PD is extensively studied. Experience with ECT 
in PD patients is promising (Rasmussen and 
Abrams, 1991; Kellneretal.,1994). Independent 
of effects on psychiatric symptoms, ECT 
commonly results in general improvement in motor 
functions (Pridmore and Pollard, 1996). Motor 
rigidity and bradykinesia improve markedly 
followed by improvement in tremors. 
Antiparkinsonian agents such as levedopa and 
amantadine used in PD have 'on-off' phenomenon. 
During ' on ' phase the drug is ' active ' and the 
motor symptoms are better. This lasts for few 
minutes to hours. During the interval period, until 
the patient receives the next dose, the drug is no 
more active and the symptoms are obvious i.e.' 
off phase'. With long term use the effectiveness 
of the drugs diminishes, so also the duration of 
symptom-free periods. When used for prolonged 
period (months to years) it invariably results in 
paradoxical worsening of the neurological 
symptoms in PD and increases the incidence of 
depression (15-25%; Koller et al.,1994}. 
Continuation may also produce independent 
dyskinetic movements adding to their disability. 
This is possibly due to hypersensitivity of 
dopaminergic system. Rarely antiparkinsonain 
agents, in particular amantadine, may precipitate 
psychosis in PD patients (Celesia & Barr,1970). 
Use of antipsychotic drug in such cases 
complicates the clinical picture. ECT in such 
cases is an alternative. Patients with the 'on-off' 
phenomenon may show considerable 
improvement with ECT (Andersen et al., 1987). 
PD patients refractory to antiparkinsonian 
agents or intolerant to their side effects with severe 
disability ( e.g., bedridden, on- off status) are 
suitable candidates for ECT Dose of levodopa 
should be reduced to half to prevent emergent 
dyskinesia (levodopa and ECT together may result 
in dopaminergic surge). The adjunctive agents 
(e.g., anticholinergic drug, amantadine) should be 
discontinued before starting ECT in view of their 
potential side effects with concomitant use. Brief-
pulse, suprathreshold, non-dominant, unilateral 
ECT reduces the possible risk of cognitive side 
effects (Abrams, 1997). Change over to bilateral 
may be considered in case of no response to 
first three unilateral ECTs. The antiparkinsonian 
medication should be restarted after the course 
of ECT. Some of PD patients are either non-
responders or intolerant to antiparkinsonian 
agents. They are potential candidates for' 
maintenance ECT (Pridmore and Pollard, 1996). 
It helps to maintain improvement in motor 
symptoms without worsening the cognitive 
functions. Maintenance ECT is administered 
initially once a week and gradually made once a 
month. However treatment strategies should be 
individualized to the patient. Rarely, in PD patients 
ECT may result in transient emergent dyskinesia 
(Rasmussen and Abrams, 1991). This may be 
due increased postsynaptic dopamine receptor 
sensitivity caused by ECT. 
The beneficial effect of ECT on the motor 
symptoms of PD is highly variable in its duration; 
more so in patients who are resistant or intolerant 
to standard pharmacotherapy. In general, 
improvement begins with the first treatment, and 
is maximum after three to four ECTs. The 
improvement is maintained for two to four months 
after a course. There is preliminary evidence that 
continuation of maintenance ECT may be helpful 
in prolonging the therapeutic effects (Pridmore and 
Pollard,1996) Laterality stimulus dose (threshold 
v/s suprathreshold), duration of illness and prior 
drug treatment had no influence on outcome. 
However, the higher the age greater is the 
improvement (Rasmussen and Abrams, 1991). 
Depression in PD is endogenous rather 
than exogenous in origin (Schrag et al.,2001). 
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Nearly 50% of PD patients have depression and 
one third of them have moderate to severe 
depression (Robins, 1976). When depression is 
mild to moderate, antiparkinsonian agents and 
counselling lift it appreciably (Brown and 
McCarthy, 1990). Low dose antidepressants are 
also helpful in such conditions. PD patients may 
have marked disability due to rigidity and 
bradykinesia. Depression adds to their disability. 
Antidepressants are necessary to treat severe 
depression (Lishman,1998). Alternatively, ECT 
produces marked and early remission of 
depression (Douyon etal.,1989). ECT is preferred 
when depression is severe with melancholia/ 
psychotic symptoms, with high suicidal risk/ 
deliberate self harm or when associated with 
marked disability. Increase in dopamine at 
synaptic levels with ECT brings early remission 
of depression in PD patients ( Rasmussen and 
Abrams,1991). 
As many as 20% of PD patients may 
develop psychosis; antiparkinsonian medication 
has been implicated in the causation (Ron,2000). 
Classical antipsychotic drugs by blocking 
postsynaptic dompaminergic receptors in the 
striatum worsen the neurological symptoms of PD 
(Koller et al.,1994). Low doses of atypical 
antipsychotic drugs such as olanzepine (2.5 mg) 
or clozapine (25mg) are found usefiri to treat 
psychosis in PD (Juncos,1999). ECT may be 
preferred when the patient is intolerant to 
antipsychotic drugs, grossly psychotic, violent 
and/ or unmanageablle. How ECT works in such 
conditions without worsening symptoms of PD 
remains unexplained. ECT- induced delirium or 
memory disturbances may be minimised when 
unilateral ECT is used to treat co-morbid 
psychiatric illness associated with PD 
(Abrams,1997). 
Huntington's Disease: Huntington's disease (HD) 
is a triad of choreoathetosis, dementia and 
dominant inheritance. Though HD has a chronic 
course, antipsychotic drugs are effective in 
suppressing the movement disorder. Choheform 
movements resistant to pharmacological 
treatment improved with ECT without any 
untoward side effects (Beale et al.,1997). Very 
often psychiatric illnesses are seen along with 
HD and in some it may be the initial presentation. 
Depression is the commonest next to dementia 
(30-35% ; Folsteinetal.,1983). Six out of seven 
such patients not responding to antidepressants 
improved markedly with ECT (Lewis etal., 1996; 
Ranen et al.,1994). The two patients who had 
prominent delusions showed the greatest 
improvement. There was no worsening of cognitive 
status or movement disorder; rather the latter 
improved with ECT. However, one patient developed 
delirium and the movement disorder worsened in 
another patient. ECT should be a treatment option 
in the management of HD particularly with 
resistant depression. 
Movement disorders: Neuroleptic-induced 
movement disorders are common. These include 
extrapyramidal symptoms (EPS) such as 
parkinsonian tremors, akathisia, dystonia and 
long term side effect- tardive dyskinesia. History 
of antipsychotic drug intake must be established 
in all such cases. Stopping or reducing the dose 
of psychotropic drug brings marked response. 
Neuroleptic-induced EPS also improves 
when ECT used to treat the underlying psychiatric 
illness (Gangadhar et al.,1983; Goswamy et 
al.,1989), even in patients who continue on 
neuroleptic drugs. In patients with tardive 
dyskinesia, tardive dystonia, tardive akathisia, or 
tardive parkinsonian symptoms ECT has been 
tried with promising results. It is particularly useful 
in tardive dystonia. However data on maintenance 
ECT in these patients is limited. 
ECT was found useful in buccolingual or 
orofacial dyskinesia induced by long term 
antipsychotic medications (Abrams, 1997). 
Improvement in dyskinetic movements was 
maintained until one year (Gosek and 
Weller, 1998). In all these patients the underlying 
psychiatric illness (either psychosis or secondary 
depression) remitted with ECT. Most patients 
showed improvement after 3-4 ECTs. However, 
Yassa et al.(1990) in their prospective study found 
improvement in dyskinetic movements in only 
one out of nine TD patients. 
Severe dystonic gait posture (Kwentus et 
al.,1984) and sternomastoid dystonia (Adityanjee 
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etal.,1990) improved with ECT when prescribed 
for co-morbid psychosis. The remission was 
maintained when patients were followed for one 
year. However in some patients there was 
worsening of dyskinetic movements after ECT and 
some had developed dyskinetic movements with 
ECT (Roth etal.,1988). ECT- induced dyskinetic 
movements were transient and disappeared either 
immediately or within few weeks after stopping 
ECT without any additional intervention. 
Catatonia and Neuroleptic Malignant Syndrome: 
Catatonia is a medical emergency and should be 
treated as an organic condition unless and 
otherwise proved. Presence of clouding of 
consiousness that worsens in the evening, 
perseveration and neurological signs during 
examination favour an organic basis for catatonia. 
Parenteral administration of benzodiazepines may 
relatively worsen organic catatonia. Neurological 
disorders and medical illnesses may also present 
with catatonia as a complication. Hence catatonia 
calls for immediate and thorough investigation to 
identify the causative factor. Treatment of 
underlying pathology resolves catatonia. 
Neuroleptic malignant syndrome (NMS) also 
presents with catatonic symptoms rarely as a 
side effect of neuroleptic drugs. ECT is useful in 
both these conditions. 
Catatonia: Patients with typhoid, pellagra, 
pernicious anaemia who had catatonia not 
responding to pharmacological agents improved 
adequately to ECT (Dubovsky, 1986). Thus, though 
rare, irrespective of the causative factor ECT has 
been used with success in catatonia. However, in 
the presence of underlying medical or neurological 
condition, ECT may result in further deterioration 
of clinical condition. Hence ECT should be 
judiciously used in organic catatonia explaining 
the additional risk to the patient and / or the family. 
Functional illnesses such as mania, 
depression, schizophrenia or dissociative disorder 
may present with catatonia or catatonic 
symptoms. Periodic catatonia though rare is 
associated with an extreme shift in the metabolic 
nitrogen balance (Gjessing, 1974). Majority of 
functional catatonia respond to lorazepam trial (6-
8 mg per day for at least three days; Bush et 
al.,1996). ECT is effective in those not responding 
to lorazepam (Bush et al.,1996). Antipsychotic 
drugs have also been found useful. However there 
is no single clinical trial comparing the 
effectiveness of antipsychotic drug and ECT in 
non-affective catatonia. Similarly no study has 
compared at the effectiveness of ECT with 
antidepressants in depressive catatonia. It is 
generally believed that ECT is a better choice 
compared to psychotropic drugs both in terms of 
clinical efficacy and side effects. Even the more 
malignant from- lethal catatonia (characterised by 
mutism, extreme motor excietment, clouding of 
consciouness and fever progressing to severe 
autonomic disturbances, stupor, coma and death) 
may respond to ECT (Mann etal.,1986). 
Neuroleptic Malignant Syndrome: Among all the 
psychiatric conditions, NMS has the highest 
mortality. Nearly 10% of these succumb to this 
condition (Shalevetal, 1989). Early identification 
and prompt treatment reduces the fatality. Fatality 
is reduced to less than half with the use of ECT. 
One should be cautious when ECT is used to treat 
NMS. One must withdraw all antipsychotic drugs, 
control fever, correct electrolyte imbalance and 
autonomic instability prior to ECT. 
ECT is preferred to other drugs in treating 
NMS. In addition, ECT also helps to treat the 
underlying psychiatric illness. Modification 
procedure during ECT needs to be alternated. 
Succinylcholine, a muscle relaxant may 
predispose for malignant heperthermia in NMS 
(Galloway and Denborough, 1986). Instead 
atracurium is used. In such cases anaesthesia is 
reversed using neostigmine. Besides risk, 
succinylcholine has been used successfully in 
nonactive NMS by many psychiatrists without any 
additional risk (American Psychiatric 
Association,2001). If NMS is severe 
succinylcholine increases the risk of 
hyperkalemia. It is important for patients with 
active NMS symptoms to be observed for 
metabolic or cardiovascular instability over the 
ECT course (Scheftner and Schulman, 1992) ECT 
by potentiating autonomic instability may 
precipitate cardiovascular complications in 
patients with NMS and may rare
1" "»
e,.j!t in death. 
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Multiple-monitored ECT (multiple seizure 
inductions in a single ECT session) has been 
suggested to hasten the time of recovery in severe 
NMS (McKinney and Kellner, 1997). 
Degenerative disorders: Psychiatric illnesses are 
commonly associated with degenerative disorders. 
They tend to be progressive and severely impair 
the quality of life in these patients. Hence treatment 
of psychiatric conditions needs at most atention. 
ECT has been found useful in some of these 
patients besides counselling and psychotropic 
drugs. 
Dementia: The prevalence of dementia rises 
markedly with age from about 2% in persons aged 
65-70 years to 20% in those over 80 (Lishman, 
1998). During the course there is progressive 
decline in several higher cortical functions 
including memory, thinking, comprehension and 
language. Dementia is commonly associated with 
comorbid psychiatric illnesses. A major depressive 
episode is found in approximately 10% of patients 
with dementia, minor depressive episode in 25% 
and some features of depression in 50% (Rovner 
et al.,1989). Depression when marked may be 
associated with high suicidal risk, psychomotor 
retardation, psychotic symptoms or agitation. 
ECT has been used with success. ECT induced 
cardiovascular complications can be prevented by 
thorough examination of cardiovascular system, 
active control of hypertension and looking for 
cardiac efficiency before prescribing ECT. Old age 
is at risk for ECT induced cognitive side effects. 
However, systematic studies in large populations 
have not confirmed this (Nelson et al.,1991; Price 
et al.,1989). Instead there was mild improvement 
in cognition in a small group of patients. This may 
possibly be related to improvement in 
pseudodementia in depression. However, 
disorientation immediately after ECT was profound 
and prolonged (Summers etal.,1979). 
Nonetheless, to minimise ECT- induced 
cognitive side effects one should use brief pulse 
stimulus instead of sinewave stimulus, unilateral 
instead of bilateral ECT and twice weekly instead 
of thrice weekly. EEG monitoring should be 
encouraged. Use of pulse oximeter to record heart 
rate, blood pressure and ECG throughout at ECT 
procedure is recommended in the elderly 
(American Psychiatric Association,2001). 
Neuromuscular and Neurodegenerative disorders: 
Multiple sclerosis is commonly associated with 
depression and suicjde. Depression is present in 
about 50% of patients (Ron and Logsdail,1989) 
and there is seven-fold increase in the expected 
rates of suicide (Stengager et al.,1992). Those 
not responding to antidepressants showed good 
response to ECT (Kwentus et al., 1986; Coffey et 
al.,1987). There was no worsening of the 
neurological status. The later study did not find 
any change in white matter lesion in MRI scans 
done before and after the ECT treatment. ECT 
has also been successfully used to treat 
psychiatric patients suffering from cerebral palsy, 
myasthenia gravis, muscular dystrophy and 
Friedrich's ataxia all without any complications 
(Dubovsky, 1986). 
During anaesthesia, succinylcholine used 
in patients with neuromuscular disorder may have 
potassium releasing and muscle-depolarising 
action. Increased sensitivity to succinylcholine 
may also be seen in patients with upper motor 
neuron diseae e.g., quadriplegia or amyotrophic 
lateral sclerosis ( Janis et al.,1995). Instead 
atracurium, a non-depolarising muscle blocker is 
used (Hicks, 1987). 
Guidelines for approach: Neurologically ill patients 
when prescribed ECT for their neurological 
symptoms or for associated psychiatric co-
morbidity can have relatively higher risk of ECT -
induced side effects. There can also be some 
worsening of neurological symptoms. The 
following paragraph summarizes the approach in 
neurological disorder patients prescribed ECT 
(American Psychiatric Association, 2001). 
1. The decision for ECT must be individualised 
depending upon the risk and benefits. 
2. Pre-ECT evaluation should include pertinent 
laboratory tests and specialist consultation when 
indicated. 
3. Informed consent should include increased risk. 
4. Necessary changes in ECT procedure should 
be done to minimise the risk. They may include 
altering ECT technique (stimulus dose, laterality 
and anaesthetic drugs), pharmacologic regimens 
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and monitoring procedures. 
5. Patients with increased ICP have substantially 
elevated risk with ECT; its use must be adequately 
justified in terms of risk- benefit consideration. In 
such cases, treatment modifications, such as use 
of potent antihypertensive agents, steroids, 
diuretics and hyperventilation, should be 
considered to diminish risk. 
6. Short-acting antihypertensive agents should be 
considered at the time of ECT in patients at risk 
for haemorrhagic cerebrovascular events (e.g., 
aneurysms, arteriovenous malformations). 
7.Certain neurological conditions may be 
associated with increased severity of cognitive 
dysfunction during and immediately following ECT 
e.g., dementia, brain trauma, PD and multiple 
sclerosis. This does not imply that ECT is 
contraindicated in these conditions. 
8. In patients with epilepsy, doses of 
anticonvulsant drugs should be optimised to 
maintain effective seizure control, yet still permit 
adequate seizure induction with ECT. 
9. In patients with PD, dosage of dopaminergic 
agents should be optimised to maintain control of 
motor symptoms while also adjusting for 
increasing dopaminergic effects with ECT. 
10. Neuroleptics should be avoided in NMS. In 
severe NMS nondepolarizing muscle relaxants 
should be considered at the time of ECT. Such 
patients should also be observed for metabolic 
and cardiovascular instability. 
Conclusions: ECT is used, though infrequently, 
to treat some of the neurological illnesses. These 
include PD, particularly with the 'on' & ' off' 
phenomenon, NMS, delirium and intractable 
seizure disorders. ECT seems appropriate for 
patients with a combination of an affective and a 
neurological disorder and for patients who are 
dangerously suicidal, self-destructive, agitated, 
and/ or grossly negativistic. Neurological 
diseases, including brain tumours, are not 
necessarily contraindications to the use of ECT. 
However, ECT is reserved for patients who are 
resistant or intolerant to standard medical 
treatments or who require an urgent response. 
Detailed neurological evaluation of risk 
factors should be carried out prior to ECT. 
Concurrent medications must be adjusted 
appropriately. ECT procedures must be optimised 
which may diminish the level of risk. Specific 
conditions that may be associated with 
substantially increased risk include: a) aneurysm 
or vascular malformation that might be susceptible 
to rupture with increase blood pressure, b) 
increased ICP as may occur with some brain 
tumour or other space occupying lesion and c) 
recent cerebral infarction. 
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